Wisp expands into longevity care with launch of new ‘Healthy Aging’ category
Wisp said the therapies are intended to support cellular repair, energy production and immune function
Women’s telehealth company Wisp is expanding into longevity medicine with the launch of a new “Longevity and Healthy Aging” category offering treatments including NAD+, glutathione and low-dose naltrexone.
The New York-based company said the new vertical marks its move beyond reproductive and sexual health services into what it describes as clinician-guided longevity care designed specifically for women.
The initial offering includes five treatments: glutathione and NAD+, available as nasal sprays or injections, and low-dose naltrexone (LDN), which is sometimes prescribed off-label for inflammatory or immune-related conditions.
Wisp said the therapies are intended to support cellular repair, energy production and immune function, areas the company argues are often overlooked in traditional care settings. It also sees this offering as a natural pairing with lifestyle strategies like sleep, exercise and nutrition and a complement to more traditional longevity interventions such as cardiovascular risk reduction and bone health screening.
Monica Cepak, chief executive of Wisp, said the company’s aim was to translate emerging longevity science into clinician-guided care tailored to women’s needs.
“As the telehealth market for treatments like NAD+ and glutathione becomes increasingly fragmented and expensive, women are being left behind,” Cepak said.
“Women are navigating complex hormonal transitions and immune issues that don’t fit into a standard biohacking framework.”
Significant longevity gap
The launch follows a survey commissioned by Wisp of nearly 2,000 women in the United States which found that while 75% said they prioritise long-term health in their daily choices, almost half were unsure which interventions are effective for women’s bodies. More than nine in ten respondents said telehealth could play an important role in healthy ageing, although only 11% felt current digital tools give them a sense of control over their long-term health.
Patients accessing the new category will receive asynchronous consultations with clinicians and ongoing monitoring of treatment plans through Wisp’s digital platform.
The expansion also marks the company’s entry into peptide therapies, which it plans to introduce as part of its longevity offering. While Wisp acknowledges that there are ‘valid concerns’ about peptides and that is deliberately taking a ‘cautious stance’. This includes reviews of published clinical literature, safety data, and how these therapies are already used in medical practice. Every plan it provides includes clinician review, screening, and ongoing monitoring. Wisp says it has also consciously chose to work only with partners who compound in the U.S.
Dr Shannon Chatham, medical director at Wisp, said the company sees longevity care as an extension of its broader telehealth model.
“We are helping women take control of their healthspan, not just their lifespan,” Chatham said.
“This isn’t about chasing trends, it’s about providing evidence-based care that supports women as they age.”
Founded in 2018, Wisp says it has served more than 1.8m patients across the US through online prescriptions and telehealth services covering contraception, fertility, menopause care, STI testing and at-home diagnostics. The company is majority owned by WELL Health Technologies.